Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering

Yuji Hori, Ken Ohmine, Hitoshi Katada, Yuki Noguchi, Kazuki Sato, Takeru Nambu, Lam Runyi Adeline, Gan Siok Wan, Kenta Haraya, Kazuhiisa Ozeki, Masahiko Nanami, Tatsuhiko Tachibana, Zenjiro Sampei, Taichi Kurumochi, Junichi Nezu, Kunihiro Hattori, and Tomoyuki Igawa

*Research Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan; ‡Chugai Pharmabody Research Pte. Ltd, Singapore; §Research Division, Chugai Pharmaceutical Co, Ltd, Chuo-ku, Tokyo, Japan; ¶Research Division, Chugai Pharmaceutical Co, Ltd, Kamakura, Japan

**ABSTRACT**
A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen–antibody immune complexes, which escape from lysosomal degradation using neonatal Fc receptor (FcRn)-mediated recycling. To address this, we developed an antigen-sweeping antibody that combines pH-dependent antigen binding and Fc engineering to enhance Fc receptor binding. The sweeping antibody actively eliminates the plasma antigens by increasing the cellular uptake of the immune complex and dissociating the antigens in the acidic endosome for degradation. Strong antigen sweeping can reduce the dosage, potentially achieve higher efficacy, and expand the scope of antigen space available for targeting by antibodies. In this study, to further improve the sweeping efficacy, we developed a novel antibody Fc variant by enhancing Fcγ receptor IIb (FcyRIIB) binding and modulating charge characteristics for increased cellular uptake of the immune complex, together with enhancing FcRn binding for efficient salvage of the antigen-free antibodies. Our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with antibody pharmacokinetics comparable to a wild-type human IgG1 antibody. The positive-charge substitutions enhanced uptake of the immune complex by FcyRIIB-expressing cells in vitro, which was completely inhibited by an anti-FcyRIIB antibody. This suggests that the strong in vivo sweeping efficacy improved by the charge engineering is more likely achieved by FcyRIIB-dependent uptake of the immune complex rather than nonspecific uptake. We expect this novel Fc engineering can maximize the antigen sweeping efficacy even in humans and create novel therapeutic antibodies that meet unmet medical needs for patients.

**Introduction**
The administration of a conventional antibody targeting a soluble antigen has been reported to induce antigen accumulation in plasma.1–5 This often happens because of the reduced clearance of the antigen by the administered antibody. After soluble antigens are taken up by cells, free antigens in the acidic endosome are transported to the lysosome for degradation, while the antibody–antigen immune complex is salvaged back to blood circulation by FcRn, which reduces the antigen clearance.6,7 Since antigen accumulation in plasma requires huge dosage and frequent intravenous administration to effectively neutralize the antigen, antibody engineering to suppress the antigen accumulation is needed to reduce the treatment burden for patients and their caregivers.

Antibodies that pH-dependently bind to antigens have been eagerly studied in recent years,7–16 as they could be the key to solving this problem. Such pH-dependent antibodies that show weaker affinity at acidic pH than at neutral pH are expected to dissociate the antigens in the acidic endosome.7,14 After dissociation, while the antigen-free antibody is recycled back into plasma by FcRn, the dissociated antigens are digested in the lysosome, which thus suppresses the antigen accumulation in plasma that often accompanies conventional antibodies.12–14

We previously reported on sweeping antibodies, which combine pH-dependent antigen-binding with enhanced affinity to FcRn or FcyRIIB.17–19 A sweeping antibody actively eliminates its soluble antigens from plasma by increasing the Fc receptor-mediated cellular uptake of the immune complex, which then increases the number of dissociated antigens in the endosome for degradation. Therefore, the sweeping antibody is expected to achieve lower antibody dosage and higher efficacy by increasing the neutralization capacity per antibody, and thus expand the space of antigens targetable by antibody therapeutics. However, novel antibody engineering to further enhance the sweeping efficiency is still in high demand because sweeping efficiency for some antigens by previously reported technologies could be insufficient.

Several studies show the surface charge of the antibodies had some effect on their pharmacokinetics and functions.12,20–24 Because surface-charge engineering of the variable and constant regions of a pH-dependent anti-
C5 antibody suppressed the accumulation of the antigen, the interaction between the cell membrane’s negative charge and the antibody’s positive charge can be a driving force for increasing the uptake of the immune complex and the number of the antigens degraded in the lysosome. However, positive charges in the antibody have been reported to increase antibody clearance, which must be carefully considered when engineering antibodies for therapeutic applications.

The number of the IgG antibody molecules in the immune complex also affects the sweeping efficiency. When targeting a multimeric antigen, the antibodies can form an immune complex containing multiple Fc regions, and its cellular uptake is accelerated by its binding avidity with multiple Fc receptors.

In this study, we developed a novel Fc variant by combining selectively enhanced FcyRIIb binding, charge engineering, and enhanced FcRn binding to maximize the sweeping efficiency. We used a pH-dependent antigen-binding antibody targeting latent myostatin, a soluble dimer antigen, so that immune complexes each containing multiple antibody Fc regions can form in vivo. This antibody engineering exhibited strong antigen sweeping in cynomolgus monkeys without compromising good antibody pharmacokinetics.

We also conducted an in vitro study to understand the mechanism through which cellular uptake was enhanced by charge engineering. The positive-charge substitutions increased the amount of the antibody binding to human FcyRIIb on the cell surface, which was strongly suppressed by an anti-FcyRIIb antibody. This suggests that the charge engineering further improved in vivo sweeping efficacy mainly through FcyRIIb-mediated cellular uptake, and nonspecific cellular uptake is largely not involved. This novel Fc engineering can realize stronger antigen sweeping efficacy even in humans and provide novel therapeutic antibodies that meet unmet medical needs for patients.

**Results**

**Design of antibodies for strong antigen sweeping**

We prepared two antibody variable region derivatives (non−pH-dependent antibody and pH-dependent antibody) made from the same antibody targeting latent myostatin. The antigen-binding properties of the non−pH-dependent antibody (NpH-IgG1) and pH-dependent antibody (pH-IgG1) were assessed by surface plasmon resonance (SPR) analysis and are shown in Table 1. We confirmed that the antigen binding of these antibodies was sufficiently stable for use in several experiments included in our study (stability data not shown). We also prepared Fc derivatives by introducing amino acid substitutions into IgG1 to selectively enhance FcyRIIb binding, modify the surface charge of the Fc region, and moderately enhance FcRn binding. The antibody design for strong antigen sweeping is shown in Figure 1. The binding activity of these Fc variants to each Fcy receptor was measured (Table 2, Supplemental Figure S1, S2 and Supplemental Table S1, S2).

**Fc engineering to selectively enhance FcyRIIb binding**

Previously, we reported that Fc variants with enhanced binding to FcyRIIb showed increased clearance of the soluble antigen in mice. Although a few Fc variants had enhanced human FcRn binding (huFcRIIb) binding, none of them is reported to cross-react with cynomolgus FcyRIIb (cyFcRIIb). To predict the sweeping efficacy in humans, we tried to develop a new human Fc variant whose binding levels to huFcRIIb and cyFcRIIb were similarly enhanced. This was also needed to reduce binding to activating Fcy receptors such as FcyRIIIa because it could potentially induce immune activation or cause unwanted adverse effects, depending on the disease or the mode of action of the antibody. Therefore, to make an Fc variant with the desired binding to each FcyR, we selected substitutions G236N, H1268D, and A330K, based on our previous work, and introduced them in the Fc region of IgG1. The IgG1 variants V1 (G236N), V2 (G236N/H1268D), and V3 (G236N/H1268D/A330K) were then produced and their binding activity to each Fcy receptor was measured (Table 2). V3 showed enhanced binding to both huFcRIIb and cyFcRIIb, and importantly, the levels of enhancement were comparable (by 3.06-fold and 2.86-fold, respectively). Although the affinity to cyFcRIIa of V3 was also enhanced because of the high homology between cyFcRIIa and cyFcRIIb, this Fc variant could be useful for predicting the sweeping efficacy of the antibodies in humans based on cynomolgus monkey pharmacokinetics studies.

**Effect of positive-charge substitutions on cellular uptake of immune complex and antibody pharmacokinetics**

We previously reported that charge engineering could reduce antigen accumulation in cynomolgus monkeys. To maximize the antigen sweeping efficacy, we designed Fc variants by introducing positively charged substitutions in the Fc region. We examined and introduced the substitution sets of Q311R/D413K, S400R/D413K, and Q311R/S400R/D413K into the IgG1 Fc region of a pH-dependent antibody to generate the Fc variants pl(A), pl(B), and pl(C), respectively. These substitutions did not greatly affect the binding to human and cynomolgus FcγRs (Table 2).

We examined the antigen uptake efficiency of the pH-dependent antibody (pH-IgG1) and its variants with the positive-charge substitutions in the Fc region, pH-pl(A), pH-pl(B), and pH-pl(C), by an in vitro cellular uptake assay, in which we measured the amount of fluorescently labeled antigens taken into the cells expressing human FcyRIIb (Figure 2a). These variants showed improved antigen-uptake activity compared with the wild-type IgG1.

Since the charge characteristics potentially affect the antibody pharmacokinetics, the effect of these substitutions on the antibody clearance in vivo was then evaluated using human FcRn transgenic mice. Whereas the antibody clearance was increased in pH-pl(B) and pH-pl(C), that of pH-pl(A) from plasma was mostly unaffected (Figure 2b). Because the antibody plasma half-life was also an important factor for sweeping efficiency, we chose the positive-charge substitutions used in the pH-pl(A) variant for the subsequent combination with the Fc engineering to enhance FcyRIIb binding.
**Effect of the combination of enhanced FcγRIIb binding and positive-charge substitutions on soluble antigen clearance in mice**

To evaluate the combinatorial effect of the surface-charge engineering with FcγRIIb enhanced binding, pH-V3-pI(A) was constructed by introducing the positive-charge substitutions of pI(A) into pH-V3. We confirmed that the binding affinity of pH-V3-pI(A) to huFcγRIIb is comparable to pH-V3 (Table 2). The effect of the Fc engineering on antigen clearance was evaluated in an antigen/antibody co-injection study using all human FcyR transgenic mice.27 Latent myostatin is reported to be cleaved by proteases and produce mature myostatin.29–31 To evaluate the effect of Fc engineering on antigen clearance, we need to measure not only latent myostatin concentration in plasma, but also that of mature myostatin. Therefore, we measured total myostatin concentration (mature + latent myostatin) in plasma. Consistent with the previous report using huFcγRIIb transgenic mice,17 pH-dependent antibody with FcγRIIb-enhanced binding, pH-V3, showed accelerated antigen clearance compared with pH-IgG1 and comparable antibody clearance to pH-IgG1 (Figure 3). The administration of pH-V3-pI(A) further accelerated antigen clearance compared with pH-V3 or pH-IgG1, although the antibody clearance from plasma was also increased (Figure 3). These data demonstrated that the combination of the positive-charge substitutions and FcγRIIb enhanced binding can effectively increase antigen clearance and suppress antigen accumulation.

| Ab name | Human myostatin | Cynomolgus myostatin |
|---------|-----------------|----------------------|
|         | KD pH 7.4 (M)   | KD pH 5.8 (M)       |
| NpH-IgG1| 1.78 x 10^{-10} | 2.24 x 10^{-10}     |
| pH-IgG1 | 2.85 x 10^{-10} | 3.43 x 10^{-10}     |
|         | ratio of KD at pH 5.8/pH 7.4 | ratio of KD at pH 5.8/pH 7.4 |
| NpH-IgG1| 6.22 x 10^{-11} | 6.23 x 10^{-11}     |
| pH-IgG1 | 3.48 x 10^{-5}  | 2.59 x 10^{-8}      |
|         | 0.3             | 0.3                  |
|         | 119.3           | 75.5                 |

The kinetic parameters of NpH-IgG1 and pH-IgG1 against human and cynomolgus latent myostatin were determined by processing and fitting the data to a 1:1 binding model.

**Table 1. The binding profile of NpH-IgG1 and pH-IgG1 to the latent myostatin at pH 7.4 and pH 5.8.**

![](image1.png)

**Figure 1. Design of antibodies for strong antigen sweeping.**

(a) Effect of charge substitutions on cellular uptake into FcγRIIb-expressing MDCK cells and antibody pharmacokinetics in human FcRn transgenic mouse

(b) The latent myostatin and the antibody were intravenously administered as single doses of 0.5 mg/kg for the latent myostatin and 1 mg/kg for antibody. pH-IgG1, pH-pl(A), pH-pl(B) and pH-pl(c) were each co-injected with the latent myostatin in human FcRn transgenic mouse, and the time profiles of plasma antibody concentration were shown. Each point represents the mean ± SD (n = 3 each).

![Image](image2.png)
Table 2. The binding profile of Fc variants to human and cynomolgus FcγRs and cynomolgus FcRn.

| Fc name | Substitutions | Relative binding per units against huFcγR (IgG1 = 1) | Relative binding per units against cyFcγR (IgG1 = 1) | KD for cyno FcRn (M) at pH 6.0 |
|---------|---------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------------|
|         |               | huFcγRIa | huFcγRIIa(H) | huFcγRIIa(R) | huFcγRIIa(V) | huFcγRIIb | cyFcγRIa | cyFcγRIIa2 | cyFcγRIIa3 | cyFcγRIIa(S) | cyFcγRIIa(R) |
| V1      | G236N         | 1       | 1           | 1           | 1           | 1       | 1       | 1       | 1       | 1       | 1       | 1.52.E-06       |
| V2      | G236N/H268D   | 0.61    | 0.55        | 0.69        | 2.53        | 0.04    | N.D.   | 0.96    | 1.45    | 1.89    | 2.36    | 2.15    | 1.12 | 0.1 | N.E.   |
| V3      | G236N/H268D/A330K | 0.39  | 0.91        | 0.91        | 0.86        | 0.93    | 0.93    | 0.95    | 0.95    | 0.94    | 0.96    | 0.96    | 0.95    | 0.95 | 0.9 | N.E.   |
| pI(A)   | Q311R/D413K   | 0.9     | 0.96        | 0.91        | 0.92        | 0.93    | 0.82    | 0.8     | 0.94    | 0.93    | 0.94    | 0.93    | 0.94    | 0.93 | 0.9 | N.E.   |
| pI(B)   | S400R/D413K   | 0.78    | 0.94        | 0.94        | 0.87        | 0.88    | 0.78    | 0.94    | 0.92    | 0.93    | 0.96    | 0.96    | 0.93    | 0.93 | 0.9 | N.E.   |
| pI(C)   | Q311R/S400R/D413K | 0.36  | 0.84        | 0.73        | 2.85        | 0.06    | 0.02    | N.E.    | N.E.    | N.E.    | N.E.    | N.E.    | N.E.    | N.E. | N.E. | N.E.   |
| V3-pI(A) | G236N/H268D/Q311R/A330K/D413K | 0.6   | 0.84        | 0.73        | 2.85        | 0.06    | 0.02    | N.E.    | N.E.    | N.E.    | N.E.    | N.E.    | N.E.    | N.E. | N.E. | N.E.   |
| V3-N434A | G236N/H268D/A330K/N434A | N.E. | N.E.        | N.E.        | N.E.        | N.E.    | N.E.    | N.E.    | 0.79    | 2.1     | 2.66    | 2.88    | 2.97    | 0.11 | 0.1 | 5.26.E-07 |
| V3-pI(A)-N434A | G236N/H268D/Q311R/A330K/D413K/N434A | N.E. | N.E.        | N.E.        | N.E.        | N.E.    | N.E.    | N.E.    | 0.71    | 1.97    | 2.52    | 2.76    | 2.83    | 0.1  | 0.09 | 3.55.E-07 |

The binding profile of Fc variants to FcγRs or FcRn was evaluated in SPR. The binding amount of each FcγR was normalized with the amount of the captured antibody and was presented as relative ratio to that of IgG1 to compare the binding ability of variants. For FcRn, sensorgrams were analyzed by the steady state affinity model to calculate the dissociation constant KD (mol/L). N.D. means not determined. N.E. represents not evaluated.


**Figure 3.** Effect of Fc engineering to enhance binding to human FcγRIIb combined with charge mutations on myostatin clearance and antibody pharmacokinetics in all human FcγR transgenic mice. The latent myostatin and antibodies were intravenously administered as single doses of 0.5 mg/kg for the latent myostatin and 3 mg/kg for antibody. pH-IgG1, pH-V3 and pH-V3-pl(A) were each co-injected with the latent myostatin in all human FcγR transgenic mice, and time profiles of (A) total myostatin plasma concentration and (b) antibody plasma concentration were shown. Each point represents the mean ± SD (n = 6 for pH-IgG1, n = 3 for pH-V3 and pH-V3-pl(A)). Antibody plasma concentration of pH-V3-pl(A) on day 28 was below the level of detection in all animals.

**Figure 4.** Effect of Fc engineering to enhance binding to human FcγRIIb combined with charge substitutions on myostatin clearance and antibody pharmacokinetics in cynomolgus monkeys (a) The time course of plasma total myostatin concentration after intravenous administration of 30 mg/kg of antibodies in cynomolgus monkey was shown. Each point represents the mean ± SD (n = 4 each). (b) The time course of plasma total antibody concentration after intravenous administration of 30 mg/kg of antibodies in cynomolgus monkey was shown. Each point represents the mean ± SD (n = 4 each). Plasma total myostatin concentration on day 2 to 3 in pH-V3-pl(A)-N434A group was below the level of detection in all animals.

**Effect of Fc engineering on endogenous antigen concentration in cynomolgus monkeys**

The effect of the Fc engineering on the endogenous antigen clearance was then evaluated in cynomolgus monkeys. We introduced the N434A substitution into pH-V3 and pH-V3-pl(A) to enhance FcRn binding for a longer antibody plasma half-life.32-37 We confirmed that the N434A substitution did not clearly affect the binding activity to cynomolgus FcRns, but improved the binding to cynomolgus FcRn at acidic pH (Table 2). As shown in Figure 4, the total myostatin concentration in plasma was

**Figure 5.** Binding and uptake of antigen-antibody complex on huFcγRIIb-expressing CHO cells. Alexa Fluor 488-labeled antigen-antibody (pH-IgG1, pH-V3, pH-pl(a) and pH-V3-pl(A)) complex was incubated with huFcγRIIb-expressing CHO cells or parent CHO cells for 20 min at 4°C for binding (A) or 37°C for uptake (b), and fluorescence intensity was measured by flow cytometer after washing cells with phosphate-buffered saline or acidic medium (pH 3.5), respectively. Binding and uptake in huFcγRIIb-expressing CHO cells or parent CHO cells are shown in blue and yellow, respectively. Binding and uptake in huFcγRIIb-expressing CHO cells in the presence of anti-huFcγRIIb antibody (2B6) or its isotype control antibody are shown in Orange and gray, respectively. Each bar represents mean ± SEM (n = 3).
greatly elevated by administration of NpH-IgG, while pH-IgG1 showed less total myostatin accumulation, demonstrating that the pH-dependent antigen-binding property (Table 1) was effective in suppressing antigen accumulation. pH-V3-N434A showed significantly lower total myostatin concentration than pH-IgG1 and reduced it to the baseline level, indicating that the antigen clearance can be accelerated in cynomolgus monkeys by enhancing the binding to Fcy receptors. Moreover, administration of pH-V3-pl(A)-N434A accelerated the antigen clearance even more strongly and reduced the total myostatin concentration below the baseline, whereas the antibody clearance was not obviously affected. The clearance of pH-V3-pl(A)-N434A was 4.7 mL/d/kg, whereas that of NpH-IgG1 and pH-IgG1 was 3.2 and 3.5 mL/d/kg, respectively (Figure 4). These data showed that combining pH-dependent antigen binding and Fc engineering technologies can strongly reduce the plasma antigen concentration in cynomolgus monkeys.

**Enhancement of FcyRIIb-mediated cellular uptake by Fc engineering**

It is known that the transfer of antigens–antibody immune complexes from plasma is mainly mediated by liver sinusoidal endothelial cells and/or Kupffer cells that express FcyRIIb. To elucidate the underlying mechanism of the effect of the charge substitutions on the in vivo antigen sweeping, we evaluated the binding and the cellular uptake of the immune complex by Chinese hamster ovary (CHO) cells that did or did not stably express huFcyRIIb. Alexa Fluor 488-labeled antigen and the tested antibodies, pH-IgG1, pH-V3, pH-pl(A), and pH-V3-pl(A), were incubated with the cells, and the cellular fluorescence intensity was measured by flow cytometry. Compared with pH-IgG1, pH-V3 and pH-pl(A) showed significantly higher binding and uptake, and that pH-V3-pl(A) was especially high. In contrast, they show little binding and uptake in the parent CHO cells (Figure 5). Furthermore, the enhanced binding and uptake by the Fc-engineered variants, not only in pH-V3, but also in pH-pl(A) and pH-V3-pl(A), were completely inhibited by an anti-huFcyRIIb antibody (2B6) that recognizes the Fc binding site of huFcyRIIb, although they were not inhibited by the isotype control antibody (Figure 5). These results indicate that the positive-charge substitutions further enhance FcyRIIb binding and increase FcyRIIb-mediated cellular uptake, rather than nonspecific uptake.

**Discussion**

In this study, we developed a novel Fc variant, V3-pl(A)-N434A, by combining enhanced binding to both human and cynomolgus FcyRIIb (V3), positive-charge substitutions (pl(A)), and improved FcRn binding (N434A). Combined with the pH-dependent antigen-binding property, enhanced binding to FcyRIIb (V3) significantly improved antigen sweeping from plasma in cynomolgus monkeys, which was further enhanced by the charge engineering (pl(A)).

To identify effective positive charge substitutions and their combinations, we selected and changed the amino acids found on the surface of the antibody Fc region based on the antibody structure. We then selected the desired combinations of substitutions by evaluating the efficiency of antigen uptake into cells expressing human FcyRIIb, as well as the antibody pharmacokinetics profiles and physicochemical properties. Basic amino acids are positively charged in circulating blood (neutral pH), which is where the uptake of immune complex occurs. Since the plasma membrane is negatively charged, the interaction between the cell membrane’s negative charge and the antibody’s positive charge can be a driving force for increasing the uptake of the immune complex.

We carefully monitored the physicochemical properties of the Fc variants during the engineering procedure, and we confirmed that the Fc variants were sufficiently stable in vivo to sweep antigens for weeks. This Fc engineering did not influence the thermal stability and aggregation (data not shown). We also confirmed that our positive charge substitutions did not strongly influence nonspecific binding (data not shown). We used similar Fc engineering in GYM329 and confirmed that the developability and sufficient stability of that antibody. In addition, we examined the C1q binding of pH-V3 and pH-V3-pl(A)-N434A and determined that these engineered Fc variants have greatly reduced binding to C1q (data not shown). It was theorized that some of the substitutions to enhance FcyRIIb binding may influence C1q binding because they exist in the C1q interaction region of IgG antibodies.

The strong antigen sweeping of pH-V3-pl(A)-N434A motivated us to determine the underlying cellular mechanism. Consistent with the enhanced antigen clearance in the pharmacokinetic study, the binding and uptake of Alexa Fluor 488-labeled antigen by huFcyRIIb expressing CHO cells were increased in pH-V3 and pH-pl(A) compared with pH-IgG1, and even more strongly increased in pH-V3-pl(A). Interestingly, the anti-huFcyRIIb antibody completely suppressed the binding and uptake of the immune complexes that had been enhanced by the Fc engineering technologies, not only the enhancement of FcyRIIb binding, but also the positive-charge substitutions, although they were not inhibited by the isotype control antibody. Furthermore, the lack of binding and uptake in the parent CHO cells suggested that the charge substitutions of these variants have little effect on nonspecific binding and uptake. These results indicated that the effect of these charge substitutions is to increase the binding of the antibodies to FcyRIIb on the cell surface rather than to promote nonspecific binding. This greatly increases antigen clearance from plasma in cynomolgus monkeys.

The composition of the antigen–antibody immune complex is likely to contribute to the strong antigen sweeping. Since the latent myostatin forms a dimer in plasma, the administration of the antibody can produce an immune complex that is composed of a few antigens and a few antibodies. Therefore, when the immune complex of pH-V3-pl(A)-N434A is formed, it can exhibit avidity binding to FcyRIIb and contain a few-fold more positive-charge residues than the antigen-free antibody. The effect of positive-charge substitutions on the immune complex is much stronger than that of the antigen-free antibody, leading to the strong antigen sweeping with a minimal effect on antibody pharmacokinetics. Based on this evidence, our novel Fc engineering seems to be advantageous for
sweeping antibodies that can form immune complexes containing multiple antibodies and sweeping efficiency may be reduced in the case of monomer antigen.

The pharmacokinetics of antibodies are also an important factor in sweeping efficiency. Although the effect of the charge substitutions is weaker for the antigen-free antibody than for the immune complex, its influence on antibody clearance must be carefully considered, as suggested by several reports which showed that the antibody charge may influence its pharmacokinetics profile.\textsuperscript{20-23} To minimize the negative effect on antibody pharmacokinetics, we conducted pharmacokinetics screening using human FcRn transgenic mice and selected pL(A), which showed a slightly accelerated but acceptable antibody clearance. We also applied the N434A substitution, which was previously reported for FcRn-mediated elongation of the antibody half-life.\textsuperscript{36,37} As the difference in antibody clearance of pH-V3-pL(A)-N434A compared to NpH-IgG\textsubscript{1} and pH-IgG\textsubscript{1} was within 1.5-fold in cynomolgus monkey, the N434A substitution is able to keep antibody clearance by enhancing the FcRn binding of the antigen-free antibody in the acidic endosome in spite of the introduced positive charge substitutions. Therefore, due to the enhanced FcRn binding, we expect that these charge substitutions can be applied clinically without critically affecting antibody pharmacokinetics. We previously reported that enhancing FcRn binding was effective to sweep soluble antigens.\textsuperscript{18} However, we believe that the N434A substitution used in this study is not strong enough to contribute to antigen sweeping. Although FcRn-enhancing mutation M252Y/S254T/T256E (YTE) showed stronger binding ability to FcRn than N434A (YTE > AAA > N434A),\textsuperscript{36,41} it did not enhance the antigen clearance.\textsuperscript{18}

To the best of our knowledge, this is the first report showing Fc variants that exhibit enhanced binding to both human and cynomolgus FcyRIIb similarly. The Fc region of the antibody is desired to have cross-reactivity to non-human animals, especially to cynomolgus monkeys, which have restricted gene diversity and similar FcγR expression patterns,\textsuperscript{32,42} so that the results obtained in non-human animals can be extrapolated into humans more accurately. In addition, the amount of endogenous IgG in cynomolgus monkeys, which competes with FcyRIIb binding, is much higher than in mice and comparable in humans.\textsuperscript{44-46} Cynomolgus monkeys are better suited to accurately predict sweeping efficiency and antibody pharmacokinetics in humans, which means the good cross-reactivity of our novel Fc to FcyRs is very useful for predicting these profiles in humans based on the data obtained from cynomolgus monkey studies. However, extrapolation to humans is still not ideal, for it is difficult to obtain an Fc variant that can distinguish cyFcyRIIb from cyFcyRIIa due to their high homology. As shown in Table 2, substitutions that increase cyFcyRIIb binding also enhance cyFcyRIIa binding, whereas the variant V3 successfully distinguishes huFcyRIIb from huFcyRIIa. This difference can make it harder to extrapolate monkey data to humans, especially when FcyRIIa is involved in the main mechanism of action.

In terms of antigen sweeping, pH-V3-N434A did not strongly sweep the antigen in cynomolgus monkeys. We can further engineer the Fc variant for even stronger binding to cyFcyRIIb, which is likely to achieve even stronger antigen sweeping. As discussed in the previous paragraph, however, increasing the cyFcyRIIb binding most likely enhances the cyFcyRIIa binding as well, even though these variants distinguish huFcyRIIb from huFcyRIIa. As a result, there is a large difference between huFcyRIIa binding and cyFcyRIIa binding, making it difficult to extrapolate the monkey data to humans. Given these limitations, strong antigen sweeping achieved through a combination of positive-charge substitutions and FcyRIIb-enhanced binding can greatly broaden the clinical applicability of sweeping technology.

In conclusion, we developed novel Fc variants combining positive-charge substitutions, selectively enhanced binding to both human and cynomolgus FcyRIIb, and the N434A substitution. Combined with pH-dependent antigen-binding, our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with good antibody pharmacokinetics, comparable to wild-type IgG\textsubscript{1}. We expect this novel Fc engineering to achieve stronger antigen sweeping efficacy even in humans, enabling the development of novel therapeutic antibodies that can meet the unmet medical needs of patients.

Materials and methods

Ethics statement

Mice studies were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at Chugai Pharmaceutical Co. under the approval of the company’s Institutional Animal Care and Use Committee. The company is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (http://www.aaalac.org). Cynomolgus monkey studies were also performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at Shin Nippon Biomedical Laboratories Ltd. under the approval of the company’s Institutional Animal Care and Use Committee.

Protein preparation

Recombinant latent myostatin and anti-latitude myostatin antibodies were prepared by the method described previously.\textsuperscript{29} For the preparation of FcyRs, the genes encoding the extracellular region of human and cynomolgus FcyRs were synthesized based on the sequence information obtained from the National Center for Biotechnology Information or from the results of cDNA cloning conducted in house, respectively. FcyRs were fused with His-tag at their C-terminus. FreeStyle293-F cells (Invitrogen) were transfected with the vectors encoding FcyRs. The receptors were purified from the harvested culture supernatants by using ion exchange chromatography, nickel affinity chromatography, and size exclusion chromatography.

Affinity measurement to latent myostatin

The NpH-IgG\textsubscript{1} and pH-IgG\textsubscript{1} antibodies were derived from anti-latitude myostatin antibodies.\textsuperscript{29} The kinetic parameters of these antibodies against human and cynomolgus monkey latent myostatin were evaluated at 37°C at pH 7.4 or pH 5.8 using a BIACORE\textsuperscript{\textregistered} T200 instrument. ProA/G (Pierce) was
immobilized onto all flow cells on a CM4 chip using the amine coupling kit (GE Healthcare). Anti-latent myostatin antibody and analytes were prepared in ACES pH 7.4 (20 mM ACES, 150 mM NaCl, 1.2 mM CaCl₂, 0.05% Tween 20, 0.005% NaN₃). Antibody was captured onto the sensor surface by ProA/G, and human and cynomolgus latent myostatin was used as analyte. Kinetic parameters were determined by processing and fitting the data to a 1:1 binding model using BIACORE® T200 Evaluation software, version 2.0 (GE Healthcare).

**Generation of Fc variants and analysis of FcγRs and FcRn binding**

The Fc variants were generated by introducing substitutions in the human IgG₁ constant region of an anti-latent myostatin antibody. The binding profile of these antibodies to FcγRs or FcRn was evaluated using BIACORE® T200 (GE Healthcare). Phosphate buffer pH 7.4 was used as the running buffer for the evaluation of FcγRs, whereas phosphate buffer pH 6.0 was used for that of FcRn, and the measurements were conducted at 25°C. Mouse anti-human IgG kappa light chain (BD Biosciences, 555789) was immobilized onto a Series S Sensor Chip CM5 (GE Healthcare) by the amine-coupling method. Antibodies were then captured on the chip to interact with each FcγR or FcRn (prepared in house) that had been diluted with the running buffer, and the binding amount of antigen was measured. The binding amount of each FcγR was normalized with the amount of the captured antibody and was presented as relative values to IgG₁ to compare the binding ability of variants. For FcRn, the sensorgrams obtained as measurement results were analyzed by the steady state affinity model using the BIACORE® Evaluation Software to calculate the dissociation constant KD (mol/L).

**Screening of charge substitutions using MDCK stable cell line**

To evaluate the rate of internalization into a human FcγRIIb-expressing cell line, we established an MDCK (Madin–Darby canine kidney) cell line constitutively expressing human FcγRIIb. Antigen–antibody complexes were formed in a culture solution with the antibody concentration being 10 mg/mL and the pHrodoRed (Life Technologies) labeled latent myostatin concentration being 2.5 mg/mL. Then these solutions were added to culture plates containing MDCK stable cell line and incubated for one hour. The fluorescence intensity of the antigen inside the cells was quantified using InCell Analyzer 6000 (GE healthcare). PHrodoRed was used to specifically detect the internalized antigen present in the acidic environment. The amount of antigen internalized per cells was presented as relative values to human IgG₁.

**Animals**

For the cynomolgus monkey study, 2–4 years old Macaca fascicularis (cynomolgus monkey) from Cambodia (Shin Nippon Biomedical Laboratories Ltd., Japan) were used. Human FcRn transgenic mice were licensed from The Jackson Laboratory (supplier’s reference, B6.Cg-Fcgr1tm1Dcr-Tg(FCGRT)32Dcr/Dcr). Mice with entirely humanized FcγRs kindly provided by Prof. Jeffrey V. Ravetch were bred and used in this study under the license agreement with The Rockefeller University (B6.Cg-Del(1Fcgr2b-Fcgr3)1Rav-Tg-FcγRIIb-Hspa2.0#1igw-Tg(FCGR2A)11Mkz-Tg(FCGR2B)#1Rav-Tg(FCGR3A)1156Rav-Tg(FCGR3B)1373Rav).²⁷

**In vivo study**

For the cynomolgus monkey study, 30 mg/kg of antibody was administered as a single dose. For human FcRn transgenic mice, 1 mg/kg of pH-IgG₁, pH-pI(A), pH-pl(B) and pH-pl (C) were co-administered with 0.5 mg/kg of the mouse latent myostatin at a single dose of 10 ml/kg into the caudal vein. For all human FcγR transgenic mice, 3 mg/kg of pH-IgG₁, pH-V3 and pH-V3-pI(A) were co-administered with 0.5 mg/kg of the human latent myostatin at a single dose of 10 ml/kg into the caudal vein. In-house prepared anti-CD4 antibody (10 mg/kg) was also administered three times (every 10 days) at a dose of 10 ml/kg into the caudal vein to suppress anti-drug antibody in all human FcγR transgenic mice. The collected blood was centrifuged immediately to separate the plasma. Since the anti-CD4 antibody had human IgG Fc, which can affect the enzyme-linked immunosorbent assay (ELISA) results, we specifically used liquid chromatography electrospray ionization tandem mass spectrometric (LC/ESI-MS/MS) to detect test antibodies in all human FcγR transgenic mice. The dose was elevated to 3 mg/kg for each test antibody in all human FcγR transgenic mice because LC/ESI-MS/MS has a higher detection limit than ELISA.

**Measurement of total antibody concentration in the pharmacokinetic study**

To measure the concentration of the administered antibodies in monkeys, anti-human IgG antibody (Antibody Solutions, AS75-P) was immobilized onto maxisorp 96-well plates overnight before incubating in blocking buffer. Antibody calibration curve samples, quality control samples, and plasma samples were incubated on plates for 1 hour at room temperature before washing. Next, anti-human IgG-horseradish peroxidase (HRP) (Southern Biotech, 9040–05) was added and incubated for 30 min at room temperature before washing and ABTS substrate was incubated for 10, 20, and 30 min before detection with microplate reader at 405 nm.

To measure the concentration of the administered antibodies in human FcRn transgenic mice, Goat Anti-Human IgG (γ-chain specific) Biotin conjugate (Southern Biotech, 2040–08) was added to react for 1 hour at room temperature. Then, Streptavidin-PolyHRP80 (Stereospecific Detection Technologies) was added to react for 1 hour at room temperature, and chromogenic reaction was carried out using TMB One Component HRP Microwell Substrate (BioFX Laboratories) as a substrate. After stopping the reaction with 1 N sulfuric acid (Showa Chemical), the absorbance at 450 nm was measured by a microplate reader. The antibody concentrations were calculated based on the response of the calibration curve using the analytical software SOFTmax PRO (Molecular Devices).
The concentration of the administered antibodies in all human FcγR transgenic mice was measured by LC/ESI-MS/MS. Antibody calibration curve samples, quality control samples, and plasma samples were added to Ab-Capture Mag (ProteNova) and allowed to incubate for 2 hours at room temperature. Next, the magnetic beads were recovered from samples and washed. After washing, the magnetic beads were suspended in 7.5 mol/L urea, 8 mmol/L dithiothreitol, and 1 μg/mL lysozyme (chicken egg white) in 50 mmol/L ammonium bicarbonate and the suspended samples were incubated for 45 min at 56°C. Then, 500 mmol/L iodoacetamide was added and the samples were incubated for 30 min at 37°C in the dark. Next, Lysyl Endopeptidase digestion was carried out by adding Lysyl Endopeptidase for Biochemistry (Wako) and the samples were incubated for 3 hours at 37°C. Subsequently, tryptic digestion was carried out by adding sequencing grade modified trypsin (Promega). Samples were allowed to digest while mixing overnight at 37°C, and quenched by adding 10% trifluoroacetic acid. LC/ESI-MS/MS was performed using a Xevo TQ-S triple quadrupole instrument (Waters) equipped with 2D I-class UPLC (Waters). The concentration in mice plasma was calculated from the calibration curve using the analytical software Masslynx Ver.4.1 (Waters).

**Measurement of total myostatin concentration in the pharmacokinetic study**

The concentration of the total (mature + latent) myostatin in mouse and monkey plasma was measured by electrochemiluminescence. BIOTIN TAG labeled anti-mature myostatin antibody was coated onto a MULTI-ARRAY 96-well streptavidin plate (Meso Scale Discovery) before incubating in blocking buffer for 2 hours at room temperature in the cynomolgus monkey study. In-house prepared anti-mature myostatin antibody was immobilized to a MULTI-ARRAY 96-well plate by incubating overnight at 4°C in mouse studies. Myostatin calibration curve samples, quality control samples, and plasma samples were incubated with Glycine-HCl (pH 2.5) for 10 min, then, the samples were applied to the antibody plate and incubated for 1 hour on the plate at room temperature before washing. Next, SULFO TAG labeled anti-mature myostatin antibody (in-house prepared) was added and the plate was incubated for 1 hour at room temperature before washing in the cynomolgus monkey study. BIOTIN TAG labeled anti-mature myostatin antibody (in-house prepared) was added and the plate was incubated for 1 hour at room temperature before washing, and then the SULFO TAG labeled streptavidin (Meso Scale Discovery) was added and the plate was incubated for 1 hour at room temperature before washing in mouse plasma. Read Buffer T (x2) (Meso Scale Discovery) was immediately added to the plate and the signal was detected by SECTOR Imager 2400 (Meso Scale Discovery). The total myostatin concentration was calculated based on the response of the calibration curve using the analytical software SOFTmax PRO (Molecular Devices).

**Uptake and binding assay of immune complex**

The human latent myostatin was labeled with Alexa Fluor 488 (Invitrogen). The Alexa Fluor 488-labeled human latent myostatin and anti-latent myostatin antibodies, pH-IgG1, pH-V3, pH-pI(A) and pH-V3-pI(A) were mixed by equal ratio so that the final concentrations of them were 67 nM. Then the antigen–antibody mixture solution was incubated with 2 × 10^5 huFcγRIIB-expressing CHO cells or parent CHO cells for 20 min at 4°C for binding and 37°C for uptake. To inhibit FcγRIIB-mediated binding and uptake, anti-huFcγRIIB antibody (Clone 2B6; Creative Biolabs, TAB-036WM), which was reported to recognize the Fc binding site of huFcγRIIb,^40^ and its isotype control antibody (R&D systems, MAB002) were used. After incubation, cells were washed with phosphate-buffered saline for binding or acidic medium (pH 3.5) for uptake to remove cell surface-bound antigen and antibody. Cellular fluorescence was measured by FACS Canto II (Becton, Dickinson and Company). Binding and uptake amount are represented by the geometric mean of the fluorescence intensity.

**Acknowledgments**

The authors acknowledge all the research colleagues in Chugai Pharmaceutical Co., Ltd., Chugai Research Institute for Medical Science, Inc., and Chugai Pharmabody Research Pte, Ltd. for their excellent experimental assistance, technical support and helpful discussions. We especially thank Koichi Jishage, Otoya Ueda, Yosuke Kawase, Hiromi Tateishi, Masahiro Morita, Mami Kakefuda, Kanako Hara, and Kaoru Matsumoto for manipulation of mice embryos and breeding the transgenic mice, and Jacob Davis for review of the manuscript.

**Disclosure statement**

All the authors are employees and/or shareholders of Chugai. YH, HK, TK and TI are listed as inventors of the patent, "Anti-myostatin antibodies, polypeptides containing variantFc regions, and methods of use" (WO/2017/104783). These do not alter the authors’ adherence to all the mAbs policies on sharing data and materials.

**Funding**

This work was fully supported by Chugai Pharmaceutical Co., Ltd. Funding to pay the Open Access publication charges for this article was provided by Chugai Pharmaceutical Co., Ltd.

**ORCID**

Gan Siok Wann [http://orcid.org/0000-0002-6982-4492](http://orcid.org/0000-0002-6982-4492)
Taichi Kuramochi [http://orcid.org/0000-0001-7242-7124](http://orcid.org/0000-0001-7242-7124)

**References**

1. Martin PL, Cornacoff J, Prabhakar U, Lohr T, Treacy G, Sutherland JE, Hersey S, Martin E. Reviews preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-alpha in cynomolgus macaques. J Immunotoxicol. 2005 Jul 1;1(3):131–39. doi:10.1080/15476910490894904.
Jayson GC, Mulatero C, Ranso M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer. 2005 Mar;41(4):555–63. doi:10.1016/j.ejca.2004.11.021.

Harington JF, Gerlag DM, Smoots TJ, Baeten D, van den Bosch F, Bremsihan B, Breedeweld FC, Dinh JH, Legay F, Gram H, et al. Randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2387–92. doi:10.1002/art.21975.

Byrd JC, O’Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448–55. doi:10.1158/1078-0432.CCR-06-1463.

Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruxio JJ. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 1289m and hepcidin in cynomolgus monkeys. Aaps j. 2010 Dec;12(4):646–57. doi:10.1208/s12248-010-9222-0.

Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993 Aug 1;151(3):1235–44.

Devanaboyina SC, Lynch SM, Ober RJ, Ram S, Kim D, Puig-Canto A, Breen S, Kasturirangan S, Fowler S, Peng L, et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. Mabs. 2013 Nov-Dec;5(6):851–59. doi:10.1080/mabs.2013.985993.

Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta. 2014 Nov;1844(11):1943–50. doi:10.1016/j.bbabap.2014.08.003.

Murtaga ML, Fanning SW, Sharma TM, Terry AM, Horn JR. A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. Protein Sci. 2011 Sep;20(9):1619–31. doi:10.1002/pro.696.

Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012 Mar 30;287(14):11090–97. doi:10.1074/jbc.M111.319764.

Henne KR, Ason B, Howard M, Wang W, Sun J, Higbee J, Tang J, Matsuda KC, Xu R, Zhou L, et al. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. J Pharmacol Exp Ther. 2015 Apr;353(1):119–31. doi:10.1124/jpet.114.221242.

Sampei Z, Hayara K, Tachibana T, Fukuzawa T, Shida-Kawazoe M, Gan SW, Shimizu Y, Ruike Y, Feng S, Kuramochi T, et al. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. Plos One. 2018;13(12):e0209509. doi:10.1371/journal.pone.0209509.

Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoaka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010 Nov;28(11):1203–07. doi:10.1038/nbt.1691.

Fukuzawa T, Sampei Z, Hayara K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuibo Y, Tai H, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017 Apr 27;7(1):10800. doi:10.1038/s41598-017-01087-7.

Bonvin P, Venet S, Fontaine G, Raven U, Gueneau F, Kosco-Vilboux M, Proudfoot AE, Fischer N. De novo isolation of antibodies with pH-dependent binding properties. Mabs. 2015;7(2):294–302. doi:10.1080/19420862.2015.1006993.

Schröter C, Günther R, Rhiel L, Becker S, Toleikis L, Doerner A, Becker J, Schönemann A, Nasu D, Neuteboom B, et al. A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. Mabs. 2015;7(1):138–51. doi:10.1080/19420862.2014.985993.

Iwayanagi Y, Igawa T, Maeda A, Haraya K, Wada NA, Shibahara N, Ohmine K, Nambu T, Nakamura G, Mimoto F, et al. Inhibitory FcRiib-mediated soluble antigen clearance from plasma by a pH-dependent antigen-binding antibody and its enhancement by Fe engineering. J Immunol. 2015 Oct 1;195(7):3198–205. doi:10.4049/jimmunol.1401470.

Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One. 2013;8(5):e63236. doi:10.1371/journal.pone.0063236.

Igawa T, Haraya K, Hattori K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol Rev. 2016 Mar;270(1):132–51. doi:10.1111/imr.12392.

Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang J, Meng YG, Eigenbrot C, Pantua H, Diao J, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. Mabs. 2014;6(5):1255–64. doi:10.1080/mabs.29809.

Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010 May;23(5):385–92. doi:10.1093/protein/gzq009.

Datta-Mananan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without out affecting pl reduces non-specific binding and improves the pharmacokinetics. Mabs. 2015;7(3):483–93. doi:10.1080/19420862.2015.1066966.

Sampei Z, Igawa T, Soeda T, Okuyama-Nishiya H, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. Plos One. 2013;8(2):e57479. doi:10.1371/journal.pone.0057479.

Rujas E, Leaman DP, Insauti S, Ortigas-Pascual L, Zhang L, Zwick MB, Nieva JL. Functional optimization of broadening neutralizing HIV-1 antibody 10E8 by promotion of membrane interactions. J Virol. 2018 Apr 15;92(8). doi:10.1128/JVI.02249-17.

Mimoto F, Katada H, Kadono S, Igawa T, Kuramoto T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K. Engineered antibody Fc variant with selectively enhanced FcYRiib binding over both FcYRiib(R131) and FcYRiib(R131). Protein Eng Des Sel. 2013 Oct;26(10):589–98. doi:10.1093/protein/gpz022.

Chyu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowsky DE, Desjarlais JR. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIB with Fc-engineered antibodies. Mol Immunol. 2008 Sep;45(15):3926–33.

Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcy receptor structural and functional diversity. Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6181–86. doi:10.1073/pnas.1203954109.

Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanesian L, Choi EY, Shafter DJ, et al. The MHC class I-like IgG receptor controls
perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003 Apr 1;170(7):3528–33. doi:10.4049/jimmunol.170.7.3528.

29. Muramatsu H, Kuramochi T, Katada H, Ueyama A, Ruike Y, Ohmine K, Shida-Kawaoz M, Miyano-Nishizawa R, Shimizu Y, Okuda M, et al. Novel myostatin-specific antibody enhances muscle strength in muscle disease models. Sci Rep. 2021 Jan 25;11(1):2160. doi:10.1038/s41598-021-81669-8.

30. Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021 May 3;131(9). doi:10.1172/JCI114372.

31. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15842–46. doi:10.1073/pnas.2534946100.

32. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006 Jan 1;176(1):346–56. doi:10.4049/jimmunol.176.1.346.

33. Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006 Aug 18;281(33):23514–24. doi:10.1074/jbc.M604292200.

34. Zalevsky I, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010 Feb;28(2):157–59. doi:10.1038/nbt.1601.

35. Maeda A, Iwayanagi Y, Haraya K, Tachibana T, Nakamura G, Nambu T, Esaki K, Hattori K, Igawa T. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs. 2017 Jul;9(5):845–53. doi:10.1080/19420862.2017.1314873.

36. Petkova SB, Aiklesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in hormonally mediated autoimmune disease. Int Immunol. 2006 Dec;18(12):1759–69. doi:10.1093/intimm/dxl110.

37. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-α (alpha) antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos. 2010 Apr;38(4):600–05. doi:10.1124/dmd.109.031310.

38. Johansson AG, Løvdal T, Magnusson KE, Berg T, Skogh T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology. 1996 Jul;24(1):169–75. doi:10.1002/hep.510240128.

39. Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, Robinson JM, Anderson CL. FcγRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol. 2012 Nov 15;189(10):4981–88. doi:10.4049/jimmunol.1202017.

40. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S. Monoclonal antibodies capable of discriminating the human inhibitory Fcy-receptor IIB (CD32B) from the activating Fcy-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. 2007 Jul;121(3):392–404. doi:10.1111/j.1365-2567.2007.02588.x.

41. Kang C, Xia L, Chen Y, Zhang T, Wang Y, Zhou B, You M, Yuan Q, Tseng CM, An Z, et al. A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys. Protein Cell. 2018 Jan;9(1):130–34. doi:10.1007/s13238-017-0438-y.

42. Haj AK, Arbanas JM, Yamniuk AP, Karl JA, Bussan HE, Drinkwater KY, Graham ME, Eriksen AJ, Prall TM, Moore K, et al. Characterization of Maurititan cynomolgus macaque FcγR alleles using long-read sequencing. J Immunol. 2019 Jan 1;202(1):151–59. doi:10.4049/jimmunol.1800843.

43. Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, Heusser C. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol. 2012 May 1;188(9):4405–11. doi:10.4049/jimmunol.1200090.

44. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Mejide LM, Fernandez-Merino C, Vidal C. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008 Jan;151(1):42–50. doi:10.1111/j.1365-2249.2007.03545.x.

45. Cole MF, Bowen WH. Immunoglobulins A, G, and M in serum and in some secretions of monkeys (Macaca fascicularis syn. irus). Infect Immun. 1976 May;13(5):1354–59. doi:10.1128/iai.13.5.1354-1359.1976.

46. Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs. 2013 May-Jun;5(3):397–405. doi:10.4161/mabs.23836.